Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Icecure MedicalICCM -5.04%46 3-Year EBITDA Growth Rate is 18.90% as of Jun. 2026, which is 3% above its 10-year median of 18.30. GuruFocus rates ICCM with a GF Score™ of 46/100 and a GF Value™ of $21.07 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Icecure Medical ranks better than 64.49% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 18.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 1.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 8.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Icecure Medical was 54.50% per year. The lowest was -12.70% per year. And the median was 18.30% per year.
Icecure Medical (NAS:ICCM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Icecure Medical 3-Year EBITDA Growth Rate Related Terms
ICCM vs NXL, ADGM, ALRTF: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Icecure Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Icecure Medical 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Icecure Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Icecure Medical's 3-Year EBITDA Growth Rate falls into.
Icecure Medical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 18.90% mean?
Icecure Medical (ICCM) has a 3-Year EBITDA Growth Rate of 18.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Icecure Medical and its competitors. This is near median its historical median of 18.30. According to the industry distribution chart, Icecure Medical ranks #245 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 35.5%.
Is Icecure Medical's 3-Year EBITDA Growth Rate too high?
Icecure Medical's current 3-Year EBITDA Growth Rate of 18.90% is near median its 10-year median of 18.30. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Icecure Medical's value of 18.90% is 133.3% above this industry median. Based on the distribution chart, Icecure Medical ranks #245 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Icecure Medical has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Icecure Medical's 3-Year EBITDA Growth Rate compare to NXL and ADGM?
According to the Medical Devices & Instruments industry distribution chart, Icecure Medical ranks #245 out of 690 companies for 3-Year EBITDA Growth Rate. This puts Icecure Medical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Icecure Medical's value of 18.90% is 133.3% above this benchmark. While the company's 10-year median is 18.30 vs. the industry median of 8.10, Icecure Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Icecure Medical's current 3-Year EBITDA Growth Rate of 18.90% is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Icecure Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Icecure Medical's current 3-Year EBITDA Growth Rate is 18.90%, which is near median its own 10-year median of 18.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Icecure Medical stock overvalued right now?
Based on GuruFocus' analysis, Icecure Medical (ICCM) is currently considered Possible Value Trap. The stock's GF Value™ is $21.07, compared to a current price of $2.39 — trading 88.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 18.90%, which is near median its 10-year median of 18.30 and 133.3% above the Medical Devices & Instruments industry median of 8.10. Icecure Medical's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Icecure Medical (ICCM), the current 3-Year EBITDA Growth Rate is 18.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Icecure Medical (ICCM) Overvalued in 2026?
Based on GuruFocus' analysis, Icecure Medical stock appears to be undervalued.
The current stock price of $2.39 is trading 88.7% below its estimated GF Value™ of $21.07.
GuruFocus considers Icecure Medical to be Possible Value Trap.
Key valuation signals for ICCM:
3-Year EBITDA Growth Rate: 18.90% (near median its 10-year median of 18.30)
GF Value™: $21.07 vs. price of $2.39 (88.7% below fair value)
Industry Position: 133.3% above the Medical Devices & Instruments median (#245 of 690)
No single metric tells the full story. See the ICCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
46GF Score
Get the complete analysis for ICCM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCM has been successfully added to your 
